Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temozolomide + sargramostim + aldesleukin + interferon alfa-2b
- Development stage
- Phase 2
- Lead developer
- Saint Francis Hospital
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Temozolomide + sargramostim + aldesleukin + interferon alfa-2b is a combination chemobiotherapy regimen evaluated in a Phase II clinical trial for the treatment of unresectable stage IV metastatic melanoma. The regimen was developed and studied at the Northern California Melanoma Center at Saint Francis Memorial Hospital. It consists of temozolomide, an oral alkylating agent capable of crossing the blood-brain barrier, followed by a subcutaneous biological cocktail of granulocyte-macrophage colony-stimulating factor (GM-CSF/sargramostim), low-dose interleukin-2 (IL-2/aldesleukin), and interferon alfa-2b. This outpatient approach aims to combine the direct anti-tumor activity of chemotherapy with the systemic immune-potentiating effects of multiple cytokines to improve outcomes in patients with advanced melanoma, including those with M1c disease.
- Other names
- Temozolomide BiochemotherapyTemozolomide + GM-CSF + IL-2 + IFN-alfa-2b
02
Targets
DNACSF2R (Granulocyte-macrophage colony-stimulating factor receptor)IL2RB (IL-2 receptor beta chain)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on temozolomide + sargramostim + aldesleukin + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temozolomide + sargramostim + aldesleukin + interferon alfa-2b.